N | % | |
---|---|---|
18 | ||
M | 8 | 44.4% |
F | 10 | 55.6% |
Colorectal cancer | 38.9% | |
Breast cancer | 22.2% | |
Hepatocellular cancer | 11.1% | |
Ovarian cancer | 11.1% | |
Anal cancer | 5.6% | |
Cancer of unknown primary origin (CUP) | 5.6% | |
Non-small cell lung cancer (NSCLC) | 5.6% | |
21 | ||
Synchronous | 44.4% | |
Metachronous | 44.4% | |
No | 2 | 11.2% |
Liver only | 7 | 43.7% |
Liver + lung | 21.5% | |
Liver + bone | 6.2% | |
Liver + kidney | 6.2% | |
Liver + lung + bone + brain | 6.2% | |
Liver + bone + peritoneum | 6.2% | |
Liver + pleural + bone | 6.2% | |
Liver + retroperitoneal | 6.2% | |
Systemic therapy | 16 | 88.8% |
Liver surgery | 4 | 22.2% |
TACE | 44.4% | |
TACE + RFA | 5.6% | |
TACE + CP | 5.6% | |
CRYOTH | 5.6% | |
NO | 38.9% | |
Cardiac diseases | 33.3% | |
Pulmonary diseases | 16.7% | |
Liver diseases | 50.0% |
CR | PR | SD | PD | NE | PFS (mo) | OS (mo) | |
---|---|---|---|---|---|---|---|
N (%) | N (%) | N (%) | N (%) | N (%) | Mean ± s.d. | Mean ± s.d. | |
< 6 cm | 9 (90.0%) | 0 | 0 | 0 | 1 (10.0%) | 12.0 ± 9.2 | 15.1 ± 8.0 |
> 6 cm | 4 (36.4%) | 5 (45.4%) | 1 (9.1%) | 0 | 1 (9.1%) | 4.7 ± 5.4 | 7.9 ± 7.9 |
P value | 0.0483 | 0.0209 | 0.0322 | ||||
Colorectal cancer | 4 (50.0%) | 2 (25.0%) | 0 | 0 | 2 (25.0%) | 7.3 ± 12.1 | 12.1 ± 12.1 |
Breast cancer | 4 (80.0%) | 1 (20.0%) | 0 | 0 | 0 | 9.8 ± 7.5 | 10.6 ± 6.9 |
Hepatocellular cancer | 1 (33.3%) | 2 (66.7%) | 0 | 0 | 0 | 10.3±10.1 | 15.0 ± 7.2 |
P-value | 0.3615 | 0.8781 | 0.8379 | ||||
Distant (> 10 mm) | 2 (100%) | 0 | 0 | 0 | 0 | 6.5 ± 3.5 | 8.5 ± 0.7 |
Close (> 1 mm) | 5 (62.5%) | 1 (12.5%) | 1 (12.5%) | 0 | 1 (12.5%) | 8.0 ± 7.4 | 10.7 ± 7.3 |
Adjacent (< 1 mm) | 6 (54.5%) | 4 (36.3%) | 0 | 0 | 1 (9.2%) | 8.8 ± 9.8 | 10.2 ± 10.5 |
P-value | 0.6643 | 0.9364 | 0.9539 |
N | % | |
---|---|---|
21 | 100% | |
21 | 100% | |
Hypervascular | 2 | 9.5% |
Intermediate | 14 | 71.4% |
Hypovascular | 5 | 19.0% |
Yes | 19 | 90.5% |
No | 2 | 9.5% |
Distant (> 10 mm) | 19.0% | |
Close (1 mm to 10 mm) | 28.6% | |
Adjacent (< 1 mm) | 11 | 52.4% |
Local ablative therapy (LAT) | 0% | |
Transarterial chemoembolization (TACE) | 28.6% | |
Chemoperfusion (CP) | 4.8% | |
Treatment-naive | 14 | 66.7% |
Yes | 20 | 95.2% |
No | 1 | 4.8% |
2 | 4.8% | |
3 | 9.5% | |
4 | 4.8% | |
6 | 16 | 76.2% |
8 | 1 | 4.8% |
RESPONSE | N | % |
---|---|---|
Complete response (CR) | 13 | 61.9% |
Partial response (PR) | 5 | 23.8% |
Stable disease (SD) | 1 | 4.8% |
Progressive disease (PD) | 0 | 0% |
Lost to follow-up | 2 | 9.5% |